Cargando…

(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis

PURPOSE: Cardiac amyloidosis is a rare disorder, but it may lead to potentially life-threatening restrictive cardiomyopathy. Cardiac manifestations frequently occur in primary amyloidosis (AL) and familial amyloidosis (ATTR), but are uncommon in secondary amyloidosis (AA). Echocardiography is the me...

Descripción completa

Detalles Bibliográficos
Autores principales: Noordzij, Walter, Glaudemans, Andor W. J. M., van Rheenen, Ronald W. J., Hazenberg, Bouke P. C., Tio, René A., Dierckx, Rudi A. J. O., Slart, Riemer H. J. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3458209/
https://www.ncbi.nlm.nih.gov/pubmed/22806059
http://dx.doi.org/10.1007/s00259-012-2187-8
_version_ 1782244638591025152
author Noordzij, Walter
Glaudemans, Andor W. J. M.
van Rheenen, Ronald W. J.
Hazenberg, Bouke P. C.
Tio, René A.
Dierckx, Rudi A. J. O.
Slart, Riemer H. J. A.
author_facet Noordzij, Walter
Glaudemans, Andor W. J. M.
van Rheenen, Ronald W. J.
Hazenberg, Bouke P. C.
Tio, René A.
Dierckx, Rudi A. J. O.
Slart, Riemer H. J. A.
author_sort Noordzij, Walter
collection PubMed
description PURPOSE: Cardiac amyloidosis is a rare disorder, but it may lead to potentially life-threatening restrictive cardiomyopathy. Cardiac manifestations frequently occur in primary amyloidosis (AL) and familial amyloidosis (ATTR), but are uncommon in secondary amyloidosis (AA). Echocardiography is the method of choice for assessing cardiac amyloidosis. Amyloid deposits impair the function of sympathetic nerve endings. Disturbance of myocardial sympathetic innervations may play an important role in the remodelling process. (123)I-MIBG can detect these innervation changes. METHODS: Patients with biopsy-proven amyloidosis underwent general work-up, echocardiography and (123)I-MIBG scintigraphy. Left ventricular internal dimensions and wall thickness were measured, and highly refractile cardiac echoes (sparkling) were analysed. Early (15 min) and late (4 h) heart-to-mediastinum ratio (HMR) and wash-out rate were determined after administration of MIBG. RESULTS: Included in the study were 61 patients (30 women and 31 men; mean age 62 years; 39 AL, 11 AA, 11 ATTR). Echocardiographic parameters were not significantly different between the groups. Sparkling was present in 72 % of ATTR patients, in 54 % of AL patients and in 45 % of AA patients. Mean late HMR in all patients was 2.3 ± 0.75, and the mean wash-out rate was 8.6 ± 14 % (the latter not significantly different between the patient groups). Late HMR was significantly lower in patients with echocardiographic signs of amyloidosis than in patients without (2.0 ± 0.70 versus 2.8 ± 0.58, p < 0.001). Wash-out rates were significantly higher in these patients (−3.3 ± 9.9 % vs. 17 ± 10 %, p < 0.001). In ATTR patients without echocardiographic signs of amyloidosis, HMR was lower than in patients with the other types (2.0 ± 0.59 vs. 2.9 ± 0.50, p = 0.007). CONCLUSION: MIBG HMR is lower and wash-out rate is higher in patients with echocardiographic signs of amyloidosis. Also, (123)I-MIBG scintigraphy can detect cardiac denervation in ATTR patients before signs of amyloidosis are evident on echocardiography.
format Online
Article
Text
id pubmed-3458209
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-34582092013-07-15 (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis Noordzij, Walter Glaudemans, Andor W. J. M. van Rheenen, Ronald W. J. Hazenberg, Bouke P. C. Tio, René A. Dierckx, Rudi A. J. O. Slart, Riemer H. J. A. Eur J Nucl Med Mol Imaging Original Article PURPOSE: Cardiac amyloidosis is a rare disorder, but it may lead to potentially life-threatening restrictive cardiomyopathy. Cardiac manifestations frequently occur in primary amyloidosis (AL) and familial amyloidosis (ATTR), but are uncommon in secondary amyloidosis (AA). Echocardiography is the method of choice for assessing cardiac amyloidosis. Amyloid deposits impair the function of sympathetic nerve endings. Disturbance of myocardial sympathetic innervations may play an important role in the remodelling process. (123)I-MIBG can detect these innervation changes. METHODS: Patients with biopsy-proven amyloidosis underwent general work-up, echocardiography and (123)I-MIBG scintigraphy. Left ventricular internal dimensions and wall thickness were measured, and highly refractile cardiac echoes (sparkling) were analysed. Early (15 min) and late (4 h) heart-to-mediastinum ratio (HMR) and wash-out rate were determined after administration of MIBG. RESULTS: Included in the study were 61 patients (30 women and 31 men; mean age 62 years; 39 AL, 11 AA, 11 ATTR). Echocardiographic parameters were not significantly different between the groups. Sparkling was present in 72 % of ATTR patients, in 54 % of AL patients and in 45 % of AA patients. Mean late HMR in all patients was 2.3 ± 0.75, and the mean wash-out rate was 8.6 ± 14 % (the latter not significantly different between the patient groups). Late HMR was significantly lower in patients with echocardiographic signs of amyloidosis than in patients without (2.0 ± 0.70 versus 2.8 ± 0.58, p < 0.001). Wash-out rates were significantly higher in these patients (−3.3 ± 9.9 % vs. 17 ± 10 %, p < 0.001). In ATTR patients without echocardiographic signs of amyloidosis, HMR was lower than in patients with the other types (2.0 ± 0.59 vs. 2.9 ± 0.50, p = 0.007). CONCLUSION: MIBG HMR is lower and wash-out rate is higher in patients with echocardiographic signs of amyloidosis. Also, (123)I-MIBG scintigraphy can detect cardiac denervation in ATTR patients before signs of amyloidosis are evident on echocardiography. Springer-Verlag 2012-07-18 2012 /pmc/articles/PMC3458209/ /pubmed/22806059 http://dx.doi.org/10.1007/s00259-012-2187-8 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Noordzij, Walter
Glaudemans, Andor W. J. M.
van Rheenen, Ronald W. J.
Hazenberg, Bouke P. C.
Tio, René A.
Dierckx, Rudi A. J. O.
Slart, Riemer H. J. A.
(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis
title (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis
title_full (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis
title_fullStr (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis
title_full_unstemmed (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis
title_short (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis
title_sort (123)i-labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3458209/
https://www.ncbi.nlm.nih.gov/pubmed/22806059
http://dx.doi.org/10.1007/s00259-012-2187-8
work_keys_str_mv AT noordzijwalter 123ilabelledmetaiodobenzylguanidinefortheevaluationofcardiacsympatheticdenervationinearlystageamyloidosis
AT glaudemansandorwjm 123ilabelledmetaiodobenzylguanidinefortheevaluationofcardiacsympatheticdenervationinearlystageamyloidosis
AT vanrheenenronaldwj 123ilabelledmetaiodobenzylguanidinefortheevaluationofcardiacsympatheticdenervationinearlystageamyloidosis
AT hazenbergboukepc 123ilabelledmetaiodobenzylguanidinefortheevaluationofcardiacsympatheticdenervationinearlystageamyloidosis
AT tiorenea 123ilabelledmetaiodobenzylguanidinefortheevaluationofcardiacsympatheticdenervationinearlystageamyloidosis
AT dierckxrudiajo 123ilabelledmetaiodobenzylguanidinefortheevaluationofcardiacsympatheticdenervationinearlystageamyloidosis
AT slartriemerhja 123ilabelledmetaiodobenzylguanidinefortheevaluationofcardiacsympatheticdenervationinearlystageamyloidosis